CXCL10 and experimental autoimmune encephalomyelitis: A previous study demonstrated that treatment of an experimental autoimmune encephalomyelitis (EAE) with anti-IP-10 neutralizing antibodies reduced the accumulation of inflammatory mononuclear cells in the CNS and decreased the incidence of EAE development [29].